Clinical Game Changers in Breast Pathology: Ensuring Best Practices in Predictive Markers and Beyond


This lecture will cover the changing treatment landscape of breast cancer treatment and how breast pathology findings are used in clinical management decisions. Using a case-based approach, Dr Allison will cover pathology-relevant aspects of the most recent NCCN clinical treatment guidelines, the latest ASCO/CAP guidelines updates in predictive markers ER/PR and HER2, as well as evolving biomarkers recommended in the metastatic setting. Pathologists will learn how to apply guidelines standards in breast cancer diagnosis and serve as a consultant in gray zones.

Originally published on October 10, 2022

Lecture Presenter

Kimberly H. Allison, MD

Kimberly H. Allison, MD

Vice Chair of Education, Pathology Department
Director of Breast Pathology and Breast Pathology Fellowship
Program Director of Pathology Residency
Professor of Pathology
Stanford University School of Medicine

Dr. Allison is the director of Breast Pathology at Stanford and vice chair of education for the Department of Pathology. Her research interests include prognostic/predictive markers in breast cancer, standards in HER2 and ER testing, management of risk lesions, diagnostic criteria and diagnostic agreement in breast pathology and patient communication. She is on the editorial board for the 5th edition of the WHO Classification of Tumours of the Breast, is co-chair of the ASCO/CAP ER/PR Testing in Breast Cancer committee, was on the steering committee for the 2018 ASCO/CAP HER2 Testing Guidelines Update, and serves on the NCCN Breast Cancer Treatment Guidelines committee. She is actively involved in resident/fellow training as director of the Stanford Breast Pathology Fellowship and residency director for the Department of Pathology. Dr. Allison is also a breast cancer survivor and the author of Red Sunshine; A Story of Strength and Inspiration from a Doctor Who Survived Stage 3 Breast Cancer.


After this presentation, participants will be able to:

  • Describe the latest biomarkers in breast cancer and how they are used in clinical management
  • Apply the latest guideline ASCO/CAP and NCCN recommendations for prognostic/predictive testing in breast cancer
  • Discuss gray zones and unusual results to be aware of and advise on

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories